|
1
|
World Cancer Research Fund, . Endometrial
Cancer Statistics. Available from:. https://www.wcrf.org/preventing-cancer/cancer-statistics/endometrial-cancer-statistics/December
22–2024
|
|
2
|
Jarboe EA and Mutter GL: Endometrial
intraepithelial neoplasia. Semin Diagn Pathol. 27:215–225. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Terzic M, Aimagambetova G, Kunz J,
Bapayeva G, Aitbayeva B, Terzic S and Laganà AS: Molecular basis of
endometriosis and endometrial cancer: Current knowledge and future
perspectives. Int J Mol Sci. 22:92742021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dey DK, Krause D, Rai R, Choudhary S,
Dockery LE and Chandra V: The role and participation of immune
cells in the endometrial tumor microenvironment. Pharmacol Ther.
251:1085262023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang SE, Viallon V, Lee M, Dimou N,
Hamilton F, Biessy C, O'Mara T, Kyrgiou M, Crosbie EJ, Truong T, et
al: Circulating inflammatory and immune response proteins and
endometrial cancer risk: A nested case-control study and Mendelian
randomization analyses. EBioMedicine. 108:1053412024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Che Q, Xiao X, Liu M, Lu Y, Dong X and Liu
S: IL-6 promotes endometrial cancer cells invasion and migration
through signal transducers and activators of transcription 3
signaling pathway. Pathol Res Pract. 215:1523922019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mu QS, Li H, Ye H, Liu YD, Bai J, Yuan L,
Wang KJ, Lu KQ and Liu YL: Association of interleukin-6 and CD4+ T
cells and two-week prognosis of patients with COVID-19: A
predictive role. Eur Rev Med Pharmacol Sci. 27:4782–4791.
2023.PubMed/NCBI
|
|
8
|
Tolomeo M and Cascio A: The multifaced
role of STAT3 in cancer and its implication for anticancer therapy.
Int J Mol Sci. 22:6032021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jia ZX, Zhang Z, Li Z, Li A, Xie YN, Wu
HJ, Yang ZB, Zhang HM and Zhang XM: Anlotinib inhibits the progress
of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.
Eur Rev Med Pharmacol Sci. 25:2331–2343. 2021.PubMed/NCBI
|
|
10
|
Hu X, Li J, Fu M, Zhao X and Wang W: The
JAK/STAT signaling pathway: From bench to clinic. Signal Transduct
Target Ther. 6:4022021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han Y, Liu D and Li L: PD-1/PD-L1 pathway:
current researches in cancer. Am J Cancer Res. 10:727–742.
2020.PubMed/NCBI
|
|
12
|
Kim Y, Aiob A, Kim H, Suh DH, Kim K, Kim
YB and No JH: Clinical implication of PD-L1 expression in patients
with endometrial cancer. Biomedicines. 11:26912023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soslow RA, Tornos C, Park KJ, Malpica A,
Matias-Guiu X, Oliva E, Parkash V, Carlson J, McCluggage WG and
Gilks CB: Endometrial carcinoma diagnosis: Use of FIGO grading and
genomic subcategories in clinical practice: Recommendations of the
international society of gynecological pathologists. Int J Gynecol
Pathol. 38 (Suppl 1):S64–S74. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vitale SG, Haimovich S, Laganà AS, Alonso
L, Di Spiezio Sardo A and Carugno J; From the Global Community of
Hysteroscopy Guidelines Committee, : Endometrial polyps. An
evidence-based diagnosis and management guide. Eur J Obstet Gynecol
Reprod Biol. 260:70–77. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Y, Song YJ, Nie QB, Wang YF, Zhang M
and Mao GS: Correlations of IL-18 and IL-6 gene polymorphisms and
expression levels with onset of glioma. Eur Rev Med Pharmacol Sci.
26:1475–1483. 2022.PubMed/NCBI
|
|
17
|
Lu W, He F, Lin Z, Liu S, Tang L, Huang Y
and Hu Z: Dysbiosis of the endometrial microbiota and its
association with inflammatory cytokines in endometrial cancer. Int
J Cancer. 148:1708–1716. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang Y and Yang N: MicroRNA-20a-5p
inhibits epithelial to mesenchymal transition and invasion of
endometrial cancer cells by targeting STAT3. Int J Clin Exp Pathol.
11:5715–5724. 2018.PubMed/NCBI
|
|
19
|
Dong P, Xiong Y, Yue J, Xu D, Ihira K,
Konno Y, Kobayashi N, Todo Y and Watari H: Long noncoding RNA NEAT1
drives aggressive endometrial cancer progression via
miR-361-regulated networks involving STAT3 and tumor
microenvironment-related genes. J Exp Clin Cancer Res. 38:2952019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Huang S, Li H, Li Y, Zeng H, Hu J,
Lin Y, Cai H, Deng P, Song T, et al: STAT3 inhibitor BBI608 reduces
patient-specific primary cell viability of cervical and endometrial
cancer at a clinical-relevant concentration. Clin Transl Oncol.
25:662–672. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen CL, Hsieh FC, Lieblein JC, Brown J,
Chan C, Wallace JA, Cheng G, Hall BM and Lin J: Stat3 activation in
human endometrial and cervical cancers. Br J Cancer. 96:591–599.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chu Y, Wang Y, Peng W, Xu L, Liu M, Li J,
Hu X, Li Y, Zuo J and Ye Y: STAT3 activation by IL-6 from
adipose-derived stem cells promotes endometrial carcinoma
proliferation and metastasis. Biochem Biophys Res Commun.
500:626–631. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma G, Deng Y, Jiang H, Li W, Wu Q and Zhou
Q: The prognostic role of programmed cell death-ligand 1 expression
in non-small cell lung cancer patients: An updated meta-analysis.
Clin Chim Acta. 482:101–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao H, Wang Q, Gao Z, Yu Z, Wu Y and Lu Q:
Programmed death-ligand 1 and survival in colorectal cancers: A
meta-analysis. Int J Biol Markers. 34:356–363. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng Y, Fang YC and Li J: PD-L1
expression levels on tumor cells affect their immunosuppressive
activity. Oncol Lett. 18:5399–5407. 2019.PubMed/NCBI
|
|
26
|
Gao K, Shi Q, Gu Y, Yang W, He Y, Lv Z,
Ding Y, Cao W, Wang C and Wan X: SPOP mutations promote tumor
immune escape in endometrial cancer via the IRF1-PD-L1 axis. Cell
Death Differ. 30:475–487. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Post CCB, Westermann AM, Bosse T,
Creutzberg CL and Kroep JR: PARP and PD-1/PD-L1 checkpoint
inhibition in recurrent or metastatic endometrial cancer. Crit Rev
Oncol Hematol. 152:1029732020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, Song T, Zhou S and Kong X: YAP
promotes the malignancy of endometrial cancer cells via regulation
of IL-6 and IL-11. Mol Med. 25:322019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu M, Che Q, Liao Y, Wang H, Wang J, Chen
Z, Wang F, Dai C and Wan X: Oncostatin M activates STAT3 to promote
endometrial cancer invasion and angiogenesis. Oncol Rep.
34:129–138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y,
Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of
immune-checkpoint inhibitors in human cancers. Front Immunol.
13:9644422022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin S, Guo Y, Wen X, Zeng H and Chen G:
Increased expression of PD-L1 in endometrial cancer stem-like cells
is regulated by hypoxia. Front Biosci (Landmark Ed). 27:232022.
View Article : Google Scholar : PubMed/NCBI
|
